• Yardi Saibi Universitas Islam Negeri Syarif Hidayatullah Jakarta
  • Delina Hasan Program Studi Farmasi UIN Syarif Hidayatullah, Jalan Kertamukti No.5 Pisangan, Ciputat, Jakarta
  • Bukhoriah Safitri Program Studi Farmasi UIN Syarif Hidayatullah, Jalan Kertamukti No.5 Pisangan, Ciputat, Jakarta
  • Vidia Arlaini Anwar Akademi Farmasi IKIFA, Jl. Buaran 2 No.30 A, RW.13, Klender, Kec. Duren Sawit, Kota Jakarta Timur, Daerah Khusus Ibukota Jakarta 13470
Keywords: interaksi obat, mekanisme interaksi, level kemaknaan klinis interaksi, type 2 DM


The potency of drug interaction is higher because of the presence of comorbidities and polypharmacy in type 2 diabetes mellitus patient. This study aimed to know the potency of drug interaction event in  type 2 diabetes mellitus  patient in one of hospital in Jakarta in 2016 which have potency to cause hypoglycemia and hyperglicemia. Data was collected from medical record of type 2 diabetes mellitus patient . The design of this research was cross- sectional. Data retrieval was conducted retrospectively. The sample size in this study was 151 Diabetes mellitus type 2 patients medical record who received antidiabetes and met the inclusion and exclusion criteria. Data analysis was done statistically using  univariate analysis . Results showed that  female dominated the patient as much as 74,83% with hypertension as the most common comorbidities as much as 28,48%. There were 186 drug interaction event potency with 83,8% of them could cause hypoglicemia while the rest could cause hyperglicemia. Drug interaction with the potency that can cause either hypoglycemia and hyperglycemia that can effect the failure to get the therapeutic goal still be frequent found in patient prescription.  Drug interaction event should get appropriate attention from clinical pharmacist in hospital


Dipiro, J. T. and Talbert, R. L. (2014) Pharmacotherapy A Pathophysiologic Approach. 9th edn. Edited by R. L. Talbert and J. T. Dipiro. New york: The McGraw-Hill Companies Inc.

Dobrică, E. C. et al. (2019) ‘Polypharmacy in type 2 diabetes mellitus: Insights from an internal medicine department’, Medicina, 55(8), pp. 1–10. doi: 10.3390/medicina55080436.

Elnour, A. A. (2018) ‘The long ‒ term complications of hyperglycemia in both type1 and type 2 diabetic patients’, MOJ Proteomics Bioinform, 7(5), pp. 263–264. doi: 10.15406/mojpb.2018.07.00244.

Embil, J. M. et al. (2018) ‘Hypoglycemia’, Can J Diabetes, 42, pp. 104–108. doi: 10.1016/j.jcjd.2017.10.020.

Gujjarlamudi, H. (2016) ‘Polytherapy and drug interactions in elderly’, Journal of Mid-life Health, 7(3), p. 105. doi: 10.4103/0976-7800.191021.

Hines, L. E. and Murphy, J. E. (2011) ‘Potentially Harmful Drug–Drug Interactions in the Elderly: A Review’, The American Journal of Geriatric Pharmacotherapy, 9(6), pp. 364–377. doi: 10.1016/j.amjopharm.2011.10.004.

Kementerian Kesehatan RI (2014) Pusat Data dan Informasi Kementerian Kesehatan RI Situasi dan analisis Diabetes.

Kementrian Kesehatan RI (2019) Laporan Nasional Riskesdas 2018. Jakarta. Available at: http://labdata.litbang.kemkes.go.id/images/download/laporan/RKD/2018/Laporan_Nasional_RKD2018_FINAL.pdf.

Kim, H. A. et al. (2014) ‘Prevalence and predictors of polypharmacy among Korean elderly’, PLoS ONE, 9(6). doi: 10.1371/journal.pone.0098043.

Lastra, G. et al. (2014) ‘Type 2 diabetes mellitus and hypertension: An update’, Endocrinology and Metabolism Clinics of North America, 43(1), pp. 103–122. doi: 10.1016/j.ecl.2013.09.005.

Lira, C. P., Lolo, W. A. and Wewengkang, D. S. (2017) ‘Potensi Drug Related Problems ( DRPs ) Penggunaan Obat Antidiabetes Pada Pasien Diabetes Melitus Tipe 2 Di Instalasi Rawat Inap Rumah Sakit Kalooran Gmim Amurang’, PHARMACON Jurnal Ilmiah Farmasi, 6(4).

Manjusha, S., Amit, M. and Ronak, S. (2014) ‘Association of pharmaceutical teachers of India a study on prescribing pattern and potential drug-drug interactions in type 2 diabetes mellitus inpatients’, Indian Journal of Pharmacy Practice, 7(1), pp. 7–12.

Marczynski, M. A. et al. (2016) ‘Unsatisfactory glycemic control in type 2 diabetes mellitus patients: Predictive factors and negative clinical outcomes with the use of antidiabetic drugs’, Brazilian Journal of Pharmaceutical Sciences, 52(4), pp. 801–812. doi: 10.1590/S1984-82502016000400026.

Mulyani, R. (2016) ‘Hubungan Kepatuhan Dengan Keberhasilan Terapi Berbasis Kombinasi Insulin Dan Obat Antidiabetik Oral Pada Pasien Diabetes Melitus Tipe 2 Di Instalasi Rawat Jalan Rumah Sakit Umum Daerah Ulin Banjarmasin’, Prosiding Rakernas dan Pertemuan Ilmiah Tahunan Ikatan Apoteker Indonesia 2016, pp. 116–122.

Romana, A. et al. (2012) ‘Polypharmacy leading to adverse drug reactions in elderly in a tertiary care hospital’, International Journal of Pharma and Bio Sciences, 3(3).

Srikartika, V. M. et al. (2016) ‘Analisis Faktor Yang Memengaruhi Kepatuhan Penggunaan Obat Pasien Diabetes Melitus Tipe 2’, Jurnal Manajemen dan Pelayananan Farmasi, 6(3), pp. 205–212. doi: 10.22146/jmpf.347.

Tatro, D. S. (2014) Drug Interaction Facts. 5th edn. Edited by D. S. Tatro. Lippincott Williams & Wilkins.

Willer, A. K., Herreiter, J. and Pacini, G. (2016) ‘Sex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes Mellitus’, Endocrine Reviews, 37(3), pp. 278–316. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4890267/#.

William, G., Johnson, J. williams and Leary, S. M. (2013) ‘Pharmacovigilance potential impairment of hypoglycemic control associated with drug interactions: a look at closer management needs for diabetes mellitus’, J Pharmacovigilance, 1(3), pp. 3–5. doi: 10.4172/2329-6887.100011.

World Health Organiation (2003) Adherence to long-term therapies: Evidence for action, World Health Organization. doi: 10.1016/S1474-5151(03)00091-4.

How to Cite
Saibi, Y., Hasan, D., Safitri, B., & Anwar, V. (2020). POTENSI HIPOGLIKEMIA DAN HIPERGLIKEMIA PADA PASIEN DIABETES MELITUS TIPE 2 AKIBAT INTERAKSI OBAT. Jurnal Ilmiah Ibnu Sina, 5(2), 258-267. https://doi.org/10.36387/jiis.v5i2.468